Table of Content

1 INTRODUCTION 24
1.1 OBJECTIVES OF THE STUDY 24
1.2 MARKET DEFINITION AND SCOPE 24
1.2.1 MARKETS COVERED 25
1.2.2 YEARS CONSIDERED FOR THE STUDY 26
1.3 CURRENCY 26
1.4 LIMITATIONS 26
1.5 STAKEHOLDERS 27

2 RESEARCH METHODOLOGY 28
2.1 RESEARCH APPROACH 28
2.1.1 SECONDARY RESEARCH 28
2.1.1.1 Key data from secondary sources 29
2.1.2 PRIMARY RESEARCH 30
2.1.2.1 Key data from primary sources 30
2.1.2.2 Breakdown of primaries 31
2.2 MARKET SIZE ESTIMATION 31
2.3 DATA TRIANGULATION APPROACH 34
2.4 MARKET SHARE ESTIMATION 35
2.4.1 ASSUMPTIONS FOR THE STUDY 35

3 EXECUTIVE SUMMARY 36

4 PREMIUM INSIGHTS 43
4.1 APHERESIS MARKET OVERVIEW 43
4.2 EUROPE: APHERESIS MARKET, BY APPLICATION 44
4.3 GEOGRAPHIC SNAPSHOT OF THE APHERESIS MARKET (2018) 45
4.4 GEOGRAPHIC MIX: APHERESIS MARKET, 2019–2025 (USD MILLION) 46
4.5 APHERESIS MARKET: DEVELOPING VS. DEVELOPED MARKETS,
2019 VS. 2025 (USD MILLION) 46

5 MARKET OVERVIEW 47
5.1 INTRODUCTION 47
5.2 MARKET DYNAMICS: IMPACT ANALYSIS 47
5.2.1 DRIVERS 48
5.2.1.1 Rising prevalence of chronic diseases and growing number
of trauma and injury cases 48
5.2.1.2 Increasing demand for source plasma from biopharmaceutical companies 49
5.2.1.3 Rising demand for blood components and growing concerns regarding blood safety 49
5.2.1.4 Increase in the number of complex surgical procedures 50
5.2.1.5 Favorable reimbursement for apheresis procedures 51
5.2.2 RESTRAINTS 51
5.2.2.1 High cost of apheresis devices & therapeutic apheresis procedures and installation of apheresis devices through rental model 51
5.2.2.2 Fewer blood donations using apheresis due to lack of awareness 52
5.2.2.3 Stringent donor recruitment criteria 53
5.2.3 OPPORTUNITIES 53
5.2.3.1 Apheresis for leukemia and pediatric patients 53
5.2.3.2 Emerging economies with increasing investments from
government bodies and leading players 54
5.2.4 CHALLENGES 54
5.2.4.1 Recruitment of voluntary non-remunerated donors 54
5.2.4.2 Safety of blood transfusion in developing countries 55

6 INDUSTRY INSIGHTS 56
6.1 INDUSTRY TRENDS 56
6.1.1 NEW INDICATIONS FOR PLASMA PRODUCTS 56
6.1.2 INCREASING NUMBER OF COLLABORATIONS, AGREEMENTS,
AND PARTNERSHIPS 57
6.2 PORTER’S FIVE FORCE ANALYSIS 58
6.2.1 THREAT FROM NEW ENTRANTS 58
6.2.2 THREAT FROM SUBSTITUTES 59
6.2.3 BARGAINING POWER OF SUPPLIERS 59
6.2.4 BARGAINING POWER OF BUYERS 59
6.2.5 INTENSITY OF COMPETITIVE RIVALRY 60
6.3 REGULATORY ANALYSIS 60
6.3.1 NORTH AMERICA 60
6.3.1.1 US 60
6.3.1.2 Canada 61
6.3.2 EUROPE 61
6.3.3 ASIA PACIFIC 61
6.3.3.1 Japan 61
6.3.3.2 China 62
6.3.3.3 India 63

7 APHERESIS MARKET, BY PRODUCT 64
7.1 INTRODUCTION 65
7.2 APHERESIS DISPOSABLES 66
7.2.1 RECURRENT USE OF APHERESIS DISPOSABLES TO DRIVE
GROWTH IN THIS MARKET SEGMENT 66
7.3 APHERESIS DEVICES 67
7.3.1 CENTRIFUGAL APHERESIS DEVICES 68
7.3.1.1 Increasing installation of centrifugal apheresis devices in hospitals for therapeutic apheresis drives market growth 68
7.3.2 MEMBRANE SEPARATORS 70
7.3.2.1 Difficulties in separating huge volumes of plasma from milliliters of whole blood?a key factor limiting the adoption of these devices 70

8 APHERESIS MARKET, BY PROCEDURE 73
8.1 INTRODUCTION 74
8.2 AUTOMATED BLOOD COLLECTION (DONOR APHERESIS) 75
8.2.1 INCREASING NUMBER OF BLOOD COMPONENT DONATIONS
USING APHERESIS DEVICES TO SUPPORT MARKET GROWTH 75
8.3 THERAPEUTIC APHERESIS 76
8.3.1 THERAPEUTIC APHERESIS DISPOSABLES 78
8.3.1.1 Neurological disorders 80
8.3.1.1.1 Neurological disorders hold a major share in the therapeutic apheresis disposables market 80
8.3.1.2 Blood disorders 82
8.3.1.2.1 Increasing prevalence and incidence of hematologic and genetic disorders will boost the demand for therapeutic apheresis disposables 82
8.3.1.3 Renal disorders 83
8.3.1.3.1 Therapeutic plasma exchange is regarded as one of the most useful treatment options for several renal disorders 83
8.3.1.4 Autoimmune disorders 84
8.3.1.4.1 With the introduction of novel and effective biologic agents for the treatment of various autoimmune disorders, therapeutic apheresis is indicated only in severe cases 84
8.3.1.5 Metabolic disorders 85
8.3.1.5.1 Increasing adoption of plasmapheresis for the treatment of diabetes and other metabolic disorders drives the growth of this segment 85
8.3.1.6 Cardiovascular disorders 87
8.3.1.6.1 Low-density lipoprotein (LDL) apheresis is mainly used in the treatment of cardiovascular disorders 87
8.3.1.7 Other disorders 88
8.3.2 THERAPEUTIC APHERESIS DEVICES 89
8.3.2.1 Centrifugation-based devices are one of the most commonly
adopted therapeutic apheresis devices 89

9 APHERESIS MARKET, BY TECHNOLOGY 92
9.1 INTRODUCTION 93
9.2 CENTRIFUGATION 94
9.2.1 CONTINUOUS FLOW CENTRIFUGATION 96
9.2.1.1 Continuous flow is preferred in both blood collection and therapeutic apheresis procedures 96
9.2.2 INTERMITTENT FLOW CENTRIFUGATION 97
9.2.2.1 The need for a single venipuncture site is a major factor driving the demand for intermittent flow centrifugation 97
9.3 MEMBRANE SEPARATION 98
9.3.1 HIGHER EFFICACY OF THIS TECHNOLOGY ACCOUNTS FOR ITS HIGH USAGE
IN DEVELOPED WESTERN EUROPEAN COUNTRIES AND JAPAN 98

10 APHERESIS MARKET, BY APPLICATION 101
10.1 INTRODUCTION 102
10.2 PLASMAPHERESIS 102
10.2.1 PLASMAPHERESIS IS THE LARGEST APPLICATION SEGMENT
IN THE APHERESIS MARKET 102
10.3 PLATELETPHERESIS 105
10.3.1 INCREASING DEMAND FOR PLATELETS IN TRANSFUSIONS TO
DRIVE MARKET GROWTH 105
10.4 ERYTHROCYTAPHERESIS 107
10.4.1 INCREASING DEMAND FOR RED BLOOD CELLS FOR TRANSFUSION IN SURGICAL PROCEDURES TO DRIVE MARKET GROWTH 107
10.5 LEUKAPHERESIS 108
10.5.1 INCREASING INCIDENCE AND PREVALENCE OF LEUKEMIA TO DRIVE
THE LEUKAPHERESIS MARKET 108
10.6 PHOTOPHERESIS 109
10.6.1 PHOTOPHERESIS IS EXPECTED TO GROW AT THE HIGHEST CAGR DURING
THE FORECAST PERIOD 109
10.7 OTHER APPLICATIONS 111

11 APHERESIS MARKET, BY END USER 112
11.1 INTRODUCTION 113
11.2 BLOOD COLLECTION CENTERS & BLOOD COMPONENT PROVIDERS 114
11.2.1 BLOOD COLLECTION CENTERS AND BLOOD COMPONENT PROVIDERS
HOLD A MAJOR SHARE OF THE APHERESIS MARKET 114
11.3 HOSPITALS AND TRANSFUSION CENTERS 115
11.3.1 HOSPITALS AND TRANSFUSION CENTERS SEGMENT IS EXPECTED TO
GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD 115
11.4 OTHER END USERS 116

12 APHERESIS MARKET, BY REGION 118
12.1 INTRODUCTION 119
12.2 NORTH AMERICA 120
12.2.1 US 125
12.2.1.1 The US dominates the North American apheresis market 125
12.2.2 CANADA 129
12.2.2.1 The demand for plasma protein products in Canada is on the rise, which is a key factor driving market growth 129
12.3 EUROPE 133
12.3.1 GERMANY 139
12.3.1.1 Germany is the fastest-growing market for apheresis in Europe 139
12.3.2 FRANCE 143
12.3.2.1 Increasing need for blood components to drive the market for apheresis in France 143
12.3.3 ITALY 147
12.3.3.1 Therapeutic plasma exchange and LDL apheresis are widely adopted therapeutic apheresis procedures, thereby driving market growth
in Italy 147
12.3.4 UK 150
12.3.4.1 Increasing demand for source plasma to cater to the growing consumption of plasma-derived products (IVIG) driving apheresis market growth in the UK 150
12.3.5 SPAIN 154
12.3.5.1 Growing demand for blood components and plasma-derived products for the treatment of chronic diseases in the elderly is
a key factor driving market growth in Spain 154
12.3.6 REST OF EUROPE 158
12.4 ASIA PACIFIC 162
12.4.1 CHINA 166
12.4.1.1 China accounts for the largest share of the APAC apheresis market 166
12.4.2 JAPAN 170
12.4.2.1 Increasing demand for technologically advanced products drives
the market growth in Japan 170
12.4.3 INDIA 173
12.4.3.1 In India, the increasing demand for blood components and growing applications of plasma derivatives are major factors driving the growth of the apheresis market 173
12.4.4 REST OF ASIA PACIFIC 177
12.5 LATIN AMERICA 181
12.5.1 BRAZIL 184
12.5.1.1 Brazil offers lucrative growth opportunities in the apheresis market due to an increasing number of blood and plasma donations 184
12.5.2 MEXICO 188
12.5.2.1 Rapidly growing geriatric population is a key factor driving market growth in Mexico 188
12.5.3 REST OF LATIN AMERICA 191
12.6 MIDDLE EAST & AFRICA 194
13 COMPETITIVE LANDSCAPE 199
13.1 OVERVIEW 199
13.2 MARKET SHARE ANALYSIS 200
13.2.1 GLOBAL APHERESIS MARKET SHARE ANALYSIS 200
13.2.2 GLOBAL CENTRIFUGATION MARKET SHARE ANALYSIS 201
13.2.3 GLOBAL MEMBRANE SEPARATION MARKET SHARE ANALYSIS 202
?
13.3 COMPETITIVE LEADERSHIP MAPPING 202
13.3.1 VISIONARY LEADERS 203
13.3.2 INNOVATORS 203
13.3.3 DYNAMIC DIFFERENTIATORS 203
13.3.4 EMERGING COMPANIES 203
13.4 COMPETITIVE SITUATION AND TRENDS 204
13.4.1 PRODUCT LAUNCHES & APPROVALS 204
13.4.2 EXPANSIONS 205
13.4.3 PARTNERSHIPS, AGREEMENTS, AND COLLABORATIONS 206
13.4.4 ACQUISITIONS 207

14 COMPANY PROFILES 208
(Business Overview, Products Offered, Recent Developments, Strategic overview, CompEtitive analysis)*
14.1 TERUMO BCT, INC. 208
14.2 FRESENIUS SE & CO. KGAA 211
14.3 HAEMONETICS CORPORATION 215
14.4 BAXTER INTERNATIONAL INC. 218
14.5 ASAHI KASEI MEDICAL CO. LTD. (A SUBSIDIARY OF ASAHI KASEI CORPORATION) 221
14.6 B. BRAUN MELSUNGEN AG 224
14.7 CERUS CORPORATION 226
14.8 KANEKA CORPORATION 229
14.9 KAWASUMI LABORATORIES, INC. 231
14.10 NIKKISO CO., LTD. 233
14.11 MACOPHARMA SA 235
14.12 MILTENYI BIOTEC 236
14.13 OTSUKA HOLDINGS CO., LTD. 238
14.14 MEDICA SPA 239
14.15 MALLINCKRODT PLC 240
14.16 MEDICAP CLINIC GMBH 242
14.17 LMB TECHNOLOGIE GMBH 243
14.18 BIOELETTRONICA SRL 244
14.19 INFOMED 245
14.20 CYTOSORBENTS CORPORATION 246
14.21 TORAY MEDICAL CO., LTD. 249
*Details on Business Overview, Products Offered, Recent Developments, Strategic overview, CompEtitive analysis might not be captured in case of unlisted companies.
?

15 APPENDIX 250
15.1 INSIGHTS FROM INDUSTRY EXPERTS 250
15.2 DISCUSSION GUIDE 251
15.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 256
15.4 AVAILABLE CUSTOMIZATIONS 258
15.5 RELATED REPORTS 258
15.6 AUTHOR DETAILS 259



List of Figures



FIGURE 1 APHERESIS MARKET 25
FIGURE 2 RESEARCH DESIGN 28
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE DESIGNATION, AND REGION 31
FIGURE 4 BOTTOM-UP APPROACH 33
FIGURE 5 TOP-UP APPROACH 33
FIGURE 6 DATA TRIANGULATION METHODOLOGY 34
FIGURE 7 APHERESIS MARKET, BY PRODUCT, 2019 VS. 2025 (USD MILLION) 36
FIGURE 8 APHERESIS DEVICES MARKET, BY TYPE, 2019 VS. 2025 (USD MILLION) 37
FIGURE 9 APHERESIS MARKET, BY PROCEDURE, 2019 VS. 2025 (USD MILLION) 37
FIGURE 10 THERAPEUTIC APHERESIS PROCEDURES MARKET, BY PRODUCT 2019 VS. 2025 (USD MILLION) 38
FIGURE 11 THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE 2019 VS. 2025 (USD MILLION) 38
FIGURE 12 APHERESIS MARKET, BY TECHNOLOGY, 2019 VS. 2025 (USD MILLION) 39
FIGURE 13 CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2019 VS. 2025 (USD MILLION) 40
FIGURE 14 APHERESIS MARKET, BY APPLICATION, 2019 VS. 2025 (USD MILLION) 40
FIGURE 15 APHERESIS MARKET, BY END USER, 2019 VS. 2025 (USD MILLION) 41
FIGURE 16 GEOGRAPHIC SNAPSHOT: APHERESIS MARKET 42
FIGURE 17 RISING PREVALENCE OF DISEASES AND THE GROWING NUMBER OF
TRAUMA AND INJURY CASES TO DRIVE MARKET GROWTH 43
FIGURE 18 PLASMAPHERESIS ACCOUNTED FOR THE LARGEST SHARE OF THE
EUROPEAN APHERESIS MARKET IN 2018 44
FIGURE 19 THE US ACCOUNTED FOR THE LARGEST SHARE OF THE MARKET IN 2018 45
FIGURE 20 APAC TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD 46
FIGURE 21 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH DURING THE
FORECAST PERIOD 46
FIGURE 22 NUMBER OF PEOPLE WITH CHRONIC CONDITIONS IN THE US 1995–2030 (MILLION INDIVIDUALS) 48
FIGURE 23 TYPE OF PLASMA PROCESSED WORLDWIDE, 1990–2014 (MILLION LITERS) 49
FIGURE 24 PORTER’S FIVE FORCES ANALYSIS (2018): APHERESIS MARKET 58
FIGURE 25 APHERESIS DISPOSABLES TO DOMINATE THE APHERESIS MARKET
DURING THE FORECAST PERIOD 65
FIGURE 26 AUTOMATED BLOOD COLLECTION ACCOUNTED FOR THE LARGEST SHARE
OF THE APHERESIS MARKET DURING THE FORECAST PERIOD 74
FIGURE 27 THERAPEUTIC APHERESIS DISPOSABLES TO DOMINATE THE THERAPEUTIC APHERESIS MARKET DURING THE FORECAST PERIOD 77
FIGURE 28 NEUROLOGICAL DISORDERS TO ACCOUNT FOR THE LARGEST SHARE OF THE THERAPEUTIC APHERESIS DISPOSABLES MARKET DURING THE FORECAST PERIOD 79
FIGURE 29 CENTRIFUGATION SEGMENT TO DOMINATE THE APHERESIS MARKET
DURING THE FORECAST PERIOD 93
FIGURE 30 BLOOD COLLECTION CENTERS AND BLOOD COMPONENT PROVIDERS SEGMENT TO DOMINATE THE APHERESIS MARKET DURING THE FORECAST PERIOD 113
FIGURE 31 APHERESIS MARKET: GEOGRAPHIC SNAPSHOT (2018) 119
FIGURE 32 NORTH AMERICA: APHERESIS MARKET SNAPSHOT 121
FIGURE 33 EUROPE: APHERESIS MARKET SNAPSHOT 135
FIGURE 34 ASIA PACIFIC: APHERESIS MARKET SNAPSHOT 162
FIGURE 35 KEY GROWTH STRATEGIES ADOPTED BY MARKET PLAYERS FROM 2017 TO 2019 199
FIGURE 36 GLOBAL APHERESIS MARKET SHARE, BY KEY PLAYER, 2018 200
FIGURE 37 GLOBAL CENTRIFUGATION MARKET SHARE, BY KEY PLAYER, 2018 201
FIGURE 38 GLOBAL MEMBRANE SEPARATION MARKET SHARE, BY KEY PLAYER, 2018 202
FIGURE 39 APHERESIS MARKET: COMPETITIVE LEADERSHIP MAPPING (2018) 204
FIGURE 40 TERUMO BCT, INC.: COMPANY SNAPSHOT (2018) 208
FIGURE 41 FRESENIUS MEDICAL CARE: COMPANY SNAPSHOT (2018) 211
FIGURE 42 FRESENIUS KABI: COMPANY SNAPSHOT (2018) 212
FIGURE 43 HAEMONETICS CORPORATION: COMPANY SNAPSHOT (2019) 215
FIGURE 44 BAXTER INTERNATIONAL: COMPANY SNAPSHOT (2018) 218
FIGURE 45 ASAHI KASEI CORPORATION: COMPANY SNAPSHOT (2018) 221
FIGURE 46 B. BRAUN: COMPANY SNAPSHOT (2018) 224
FIGURE 47 CERUS CORPORATION: COMPANY SNAPSHOT (2018) 226
FIGURE 48 KANEKA CORPORATION: COMPANY SNAPSHOT (2019) 229
FIGURE 49 KAWASUMI LABORATORIES: COMPANY SNAPSHOT (2019) 231
FIGURE 50 NIKKISO CO., LTD.: COMPANY SNAPSHOT (2018) 233
FIGURE 51 OTSUKA HOLDINGS COMPANY LIMITED: COMPANY SNAPSHOT (2018) 238
FIGURE 52 MALLINCKRODT PLC : COMPANY SNAPSHOT (2018) 240
FIGURE 53 CYTOSORBENTS CORPORATION: COMPANY SNAPSHOT (2018) 246
FIGURE 54 TORAY MEDICAL CO. LTD.: COMPANY SNAPSHOT (2019) 249

 

List of Tables



TABLE 1 REQUIRED UNITS OF BLOOD AND BLOOD COMPONENTS, BY TYPE OF SURGERY 50
TABLE 2 US: PAYMENT RATES FOR APHERESIS PROCEDURES, 2016–2018 51
TABLE 3 ESTIMATED BLOOD DONATIONS BY WHO REGION, 2013 52
TABLE 4 FREQUENCY OF BLOOD DONATIONS FROM HEALTHY DONORS 53
TABLE 5 APHERESIS MARKET, BY PRODUCT, 2017–2025 (USD MILLION) 65
TABLE 6 APHERESIS DISPOSABLES MARKET, BY COUNTRY, 2017–2025 (USD MILLION) 66
TABLE 7 APHERESIS DEVICES MARKET, BY TYPE, 2017–2025 (USD MILLION) 67
TABLE 8 APHERESIS DEVICES MARKET, BY COUNTRY, 2017–2025 (USD MILLION) 68
TABLE 9 LIST OF CENTRIFUGAL APHERESIS DEVICES AVAILABLE IN THE MARKET 69
TABLE 10 CENTRIFUGAL APHERESIS DEVICES MARKET, BY COUNTRY 2017–2025 (USD MILLION) 70
TABLE 11 LIST OF MEMBRANE SEPARATORS AVAILABLE IN THE MARKET 71
TABLE 12 MEMBRANE SEPARATORS MARKET, BY COUNTRY, 2017–2025 (USD MILLION) 72
TABLE 13 APHERESIS MARKET, BY PROCEDURE, 2017–2025 (USD MILLION) 74
TABLE 14 APHERESIS DEVICES USED FOR AUTOMATED BLOOD COLLECTION PROCEDURES 75
TABLE 15 AUTOMATED BLOOD COLLECTION (DONOR APHERESIS) MARKET BY COUNTRY, 2017–2025 (USD MILLION) 76
TABLE 16 THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2017–2025 (USD MILLION) 77
TABLE 17 THERAPEUTIC APHERESIS MARKET BY COUNTRY, 2017–2025 (USD MILLION) 78
TABLE 18 THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE 2017–2025 (USD MILLION) 79
TABLE 19 THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY COUNTRY 2017–2025 (USD MILLION) 80
TABLE 20 NEUROLOGICAL DISORDERS TREATED USING THERAPEUTIC APHERESIS 81
TABLE 21 NEUROLOGICAL DISORDERS: ESTIMATED DALYS, BY REGION, 2015 VS. 2030 81
TABLE 22 THERAPEUTIC APHERESIS DISPOSABLES MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2017–2025 (USD MILLION) 82
TABLE 23 THERAPEUTIC APHERESIS DISPOSABLES MARKET FOR BLOOD DISORDERS BY COUNTRY, 2017–2025 (USD MILLION) 83
TABLE 24 THERAPEUTIC APHERESIS DISPOSABLES MARKET FOR RENAL DISORDERS BY COUNTRY, 2017–2025 (USD MILLION) 84
TABLE 25 THERAPEUTIC APHERESIS DISPOSABLES MARKET FOR AUTOIMMUNE
DISORDERS, BY COUNTRY, 2017–2025 (USD MILLION) 85
TABLE 26 METABOLIC DISORDERS: ESTIMATED DALYS BY REGION 2015 VS. 2030 (THOUSANDS) 86
TABLE 27 THERAPEUTIC APHERESIS DISPOSABLES MARKET FOR METABOLIC DISORDERS, BY COUNTRY, 2017–2025 (USD MILLION) 86
TABLE 28 CARDIOVASCULAR DISORDERS: ESTIMATED DALYS BY REGION 2015 VS. 2030 (THOUSANDS) 87
TABLE 29 THERAPEUTIC APHERESIS DISPOSABLES MARKET FOR CARDIOVASCULAR DISORDERS, BY COUNTRY, 2017–2025 (USD MILLION) 88
TABLE 30 THERAPEUTIC APHERESIS DISPOSABLES MARKET FOR OTHER DISORDERS BY COUNTRY, 2017–2025 (USD MILLION) 89
TABLE 31 KEY PRODUCTS AVAILABLE IN THE MARKET FOR THERAPEUTIC APHERESIS 90
TABLE 32 THERAPEUTIC APHERESIS DEVICES MARKET, BY COUNTRY 2017–2025 (USD MILLION) 91
TABLE 33 CENTRIFUGATION VS. MEMBRANE SEPARATION 93
TABLE 34 APHERESIS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION) 94
TABLE 35 CONTINUOUS FLOW CENTRIFUGATION VS. INTERMITTENT FLOW CENTRIFUGATION 94
TABLE 36 CENTRIFUGATION MARKET: KEY PLAYERS AND PRODUCTS 95
TABLE 37 CENTRIFUGATION MARKET, BY TYPE, 2017–2025 (USD MILLION) 95
TABLE 38 CENTRIFUGATION MARKET, BY COUNTRY, 2017–2025 (USD MILLION) 96
TABLE 39 CONTINUOUS FLOW CENTRIFUGATION MARKET, BY COUNTRY 2017–2025 (USD MILLION) 97
TABLE 40 INTERMITTENT FLOW CENTRIFUGATION MARKET, BY COUNTRY 2017–2025 (USD MILLION) 98
TABLE 41 SIZE OF BLOOD COMPONENTS 99
TABLE 42 MEMBRANE SEPARATION MARKET: KEY PLAYERS AND PRODUCTS 99
TABLE 43 MEMBRANE SEPARATION MARKET, BY COUNTRY, 2017–2025 (USD MILLION) 100
TABLE 44 APHERESIS MARKET, BY APPLICATION, 2017–2025 (USD MILLION) 102
TABLE 45 TOTAL SOURCE PLASMA COLLECTION IN THE US & EUROPE 2007–2017 (MILLION LITERS) 103
TABLE 46 KEY PRODUCTS AVAILABLE FOR PLASMAPHERESIS AND THERAPEUTIC
PLASMA EXCHANGE 104
TABLE 47 APHERESIS MARKET FOR PLASMAPHERESIS, BY COUNTRY 2017–2025 (USD MILLION) 105
TABLE 48 KEY PRODUCTS AVAILABLE FOR PLATELETPHERESIS 106
TABLE 49 APHERESIS MARKET FOR PLATELETPHERESIS, BY COUNTRY 2017–2025 (USD MILLION) 106
TABLE 50 KEY PRODUCTS AVAILABLE FOR ERYTHROCYTAPHERESIS 107
TABLE 51 APHERESIS MARKET FOR ERYTHROCYTAPHERESIS, BY COUNTRY 2017–2025 (USD MILLION) 108
TABLE 52 KEY PRODUCTS AVAILABLE FOR LEUKAPHERESIS 109
TABLE 53 APHERESIS MARKET FOR LEUKAPHERESIS, BY COUNTRY 2017–2025 (USD MILLION) 109
TABLE 54 KEY PRODUCTS AVAILABLE FOR PHOTOPHERESIS 110
TABLE 55 APHERESIS MARKET FOR PHOTOPHERESIS, BY COUNTRY 2017–2025 (USD MILLION) 110
TABLE 56 KEY PRODUCTS AVAILABLE FOR OTHER APPLICATIONS OF APHERESIS 111
TABLE 57 APHERESIS MARKET FOR OTHER APPLICATIONS, BY COUNTRY 2017–2025 (USD MILLION) 111
TABLE 58 APHERESIS MARKET, BY END USER, 2017–2025 (USD MILLION) 113
TABLE 59 APHERESIS MARKET FOR BLOOD COLLECTION CENTERS AND BLOOD
COMPONENT PROVIDERS, BY COUNTRY, 2017–2025 (USD MILLION) 114
TABLE 60 NUMBER OF HOSPITALS PERFORMING BLOOD TRANSFUSIONS, BY REGION, 2015 115
TABLE 61 APHERESIS MARKET FOR HOSPITALS AND TRANSFUSION CENTERS BY COUNTRY, 2017–2025 (USD MILLION) 116
TABLE 62 APHERESIS MARKET FOR OTHER END USERS, BY COUNTRY 2017–2025 (USD MILLION) 117
TABLE 63 APHERESIS MARKET, BY REGION, 2017–2025 (USD MILLION) 120
TABLE 64 NORTH AMERICA: HEMOPHILIA PATIENTS, 2013 VS. 2017 121
TABLE 65 NORTH AMERICA: APHERESIS MARKET, BY COUNTRY, 2017–2025 (USD MILLION) 122
TABLE 66 NORTH AMERICA: APHERESIS MARKET, BY PRODUCT, 2017–2025 (USD MILLION) 122
TABLE 67 NORTH AMERICA: APHERESIS DEVICES MARKET, BY TYPE 2017–2025 (USD MILLION) 122
TABLE 68 NORTH AMERICA: APHERESIS MARKET, BY PROCEDURE 2017–2025 (USD MILLION) 122
TABLE 69 NORTH AMERICA: THERAPEUTIC APHERESIS MARKET, BY PRODUCT 2017–2025 (USD MILLION) 123
TABLE 70 NORTH AMERICA: THERAPEUTIC APHERESIS DISPOSABLES MARKET BY DISEASE TYPE, 2017–2025 (USD MILLION) 123
TABLE 71 NORTH AMERICA: APHERESIS MARKET, BY TECHNOLOGY 2017–2025 (USD MILLION) 123
TABLE 72 NORTH AMERICA: CENTRIFUGATION APHERESIS MARKET, BY TYPE 2017–2025 (USD MILLION) 124
TABLE 73 NORTH AMERICA: APHERESIS MARKET, BY APPLICATION 2017–2025 (USD MILLION) 124
TABLE 74 NORTH AMERICA: APHERESIS MARKET, BY END USER, 2017–2025 (USD MILLION) 124
TABLE 75 US: KEY MACROINDICATORS FOR THE APHERESIS MARKET 126
TABLE 76 US: APHERESIS MARKET, BY PRODUCT, 2017–2025 (USD MILLION) 126
TABLE 77 US: APHERESIS DEVICES MARKET, BY TYPE, 2017–2025 (USD MILLION) 126
TABLE 78 US: APHERESIS MARKET, BY PROCEDURE, 2017–2025 (USD MILLION) 126
TABLE 79 US: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2017–2025 (USD MILLION) 127
TABLE 80 US: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE 2017–2025 (USD MILLION) 127
TABLE 81 US: APHERESIS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION) 127
TABLE 82 US: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2017–2025 (USD MILLION) 128
TABLE 83 US: APHERESIS MARKET, BY APPLICATION, 2017–2025 (USD MILLION) 128
TABLE 84 US: APHERESIS MARKET, BY END USER, 2017–2025 (USD MILLION) 128
TABLE 85 CANADA: KEY MACROINDICATORS FOR THE APHERESIS MARKET 130
TABLE 86 CANADA: APHERESIS MARKET, BY PRODUCT, 2017–2025 (USD MILLION) 130
TABLE 87 CANADA: APHERESIS DEVICES MARKET, BY TYPE, 2017–2025 (USD MILLION) 130
TABLE 88 CANADA: APHERESIS MARKET, BY PROCEDURE, 2017–2025 (USD MILLION) 131
TABLE 89 CANADA: THERAPEUTIC APHERESIS MARKET, BY PRODUCT 2017–2025 (USD MILLION) 131
TABLE 90 CANADA: THERAPEUTIC APHERESIS DISPOSABLES MARKET BY DISEASE TYPE, 2017–2025 (USD MILLION) 131
TABLE 91 CANADA: APHERESIS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION) 132
TABLE 92 CANADA: CENTRIFUGATION APHERESIS MARKET, BY TYPE 2017–2025 (USD MILLION) 132
TABLE 93 CANADA: APHERESIS MARKET, BY APPLICATION, 2017–2025 (USD MILLION) 132
TABLE 94 CANADA: APHERESIS MARKET, BY END USER, 2017–2025 (USD MILLION) 133
TABLE 95 COLLECTIONS OF BLOOD COMPONENTS USING APHERESIS ACROSS
EUROPEAN COUNTRIES IN 2013 133
TABLE 96 EUROPE: APHERESIS MARKET, BY COUNTRY, 2017–2025 (USD MILLION) 136
TABLE 97 EUROPE: APHERESIS MARKET, BY PRODUCT, 2017–2025 (USD MILLION) 136
TABLE 98 EUROPE: APHERESIS DEVICES MARKET, BY TYPE, 2017–2025 (USD MILLION) 136
TABLE 99 EUROPE: APHERESIS MARKET, BY PROCEDURE, 2017–2025 (USD MILLION) 137
TABLE 100 EUROPE: THERAPEUTIC APHERESIS MARKET, BY PRODUCT 2017–2025 (USD MILLION) 137
TABLE 101 EUROPE: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE
TYPES, 2017–2025 (USD MILLION) 137
TABLE 102 EUROPE: APHERESIS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION) 138
TABLE 103 EUROPE: CENTRIFUGATION APHERESIS MARKET, BY TYPE 2017–2025 (USD MILLION) 138
TABLE 104 EUROPE: APHERESIS MARKET, BY APPLICATION, 2017–2025 (USD MILLION) 138
TABLE 105 EUROPE: APHERESIS MARKET, BY END USER, 2017–2025 (USD MILLION) 139
TABLE 106 INCREASING HEALTHCARE EXPENDITURE IN GERMANY 2015–2017 (USD MILLION) 139
TABLE 107 GERMANY: KEY MACROINDICATORS FOR THE APHERESIS MARKET 140
TABLE 108 GERMANY: APHERESIS MARKET, BY PRODUCT, 2017–2025 (USD MILLION) 140
TABLE 109 GERMANY: APHERESIS DEVICES MARKET, BY TYPE, 2017–2025 (USD MILLION) 140
TABLE 110 GERMANY: APHERESIS MARKET, BY PROCEDURE, 2017–2025 (USD MILLION) 141
TABLE 111 GERMANY: THERAPEUTIC APHERESIS MARKET, BY PRODUCT 2017–2025 (USD MILLION) 141
TABLE 112 GERMANY: THERAPEUTIC APHERESIS DISPOSABLES MARKET BY DISEASE TYPE, 2017–2025 (USD MILLION) 141
TABLE 113 GERMANY: APHERESIS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION) 142
TABLE 114 GERMANY: CENTRIFUGATION APHERESIS MARKET, BY TYPE 2017–2025 (USD MILLION) 142
TABLE 115 GERMANY: APHERESIS MARKET, BY APPLICATION, 2017–2025 (USD MILLION) 142
TABLE 116 GERMANY: APHERESIS MARKET, BY END USER, 2017–2025 (USD MILLION) 143
TABLE 117 FRANCE: KEY MACROINDICATORS FOR THE APHERESIS MARKET 144
TABLE 118 FRANCE: APHERESIS MARKET, BY PRODUCT, 2017–2025 (USD MILLION) 144
TABLE 119 FRANCE: APHERESIS DEVICES MARKET, BY TYPE, 2017–2025 (USD MILLION) 144
TABLE 120 FRANCE: APHERESIS MARKET, BY PROCEDURE, 2017–2025 (USD MILLION) 144
TABLE 121 FRANCE: THERAPEUTIC APHERESIS MARKET, BY PRODUCT
2017–2025 (USD MILLION) 145
TABLE 122 FRANCE: THERAPEUTIC APHERESIS DISPOSABLES MARKET BY DISEASE TYPE, 2017–2025 (USD MILLION) 145
TABLE 123 FRANCE: APHERESIS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION) 145
TABLE 124 FRANCE: CENTRIFUGATION APHERESIS MARKET, BY TYPE 2017–2025 (USD MILLION) 146
TABLE 125 FRANCE: APHERESIS MARKET, BY APPLICATION, 2017–2025 (USD MILLION) 146
TABLE 126 FRANCE: APHERESIS MARKET, BY END USER, 2017–2025 (USD MILLION) 146
TABLE 127 ITALY: KEY MACROINDICATORS FOR THE APHERESIS MARKET 147
TABLE 128 ITALY: APHERESIS MARKET, BY PRODUCT, 2017–2025 (USD MILLION) 148
TABLE 129 ITALY: APHERESIS DEVICES MARKET, BY TYPE, 2017–2025 (USD MILLION) 148
TABLE 130 ITALY: APHERESIS MARKET, BY PROCEDURE, 2017–2025 (USD MILLION) 148
TABLE 131 ITALY: THERAPEUTIC APHERESIS MARKET, BY PRODUCT 2017–2025 (USD MILLION) 148
TABLE 132 ITALY: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2017–2025 (USD MILLION) 149
TABLE 133 ITALY: APHERESIS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION) 149
TABLE 134 ITALY: CENTRIFUGATION APHERESIS MARKET, BY TYPE 2017–2025 (USD MILLION) 149
TABLE 135 ITALY: APHERESIS MARKET, BY APPLICATION, 2017–2025 (USD MILLION) 150
TABLE 136 ITALY: APHERESIS MARKET, BY END USER, 2017–2025 (USD MILLION) 150
TABLE 137 UK: KEY MACROINDICATORS FOR THE APHERESIS MARKET 151
TABLE 138 UK: APHERESIS MARKET, BY PRODUCT, 2017–2025 (USD MILLION) 151
TABLE 139 UK: APHERESIS DEVICES MARKET, BY TYPE, 2017–2025 (USD MILLION) 151
TABLE 140 UK: APHERESIS MARKET, BY PROCEDURE, 2017–2025 (USD MILLION) 152
TABLE 141 UK: THERAPEUTIC APHERESIS MARKET, BY PRODUCT, 2017–2025 (USD MILLION) 152
TABLE 142 UK: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE 2017–2025 (USD MILLION) 152
TABLE 143 UK: APHERESIS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION) 153
TABLE 144 UK: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2017–2025 (USD MILLION) 153
TABLE 145 UK: APHERESIS MARKET, BY APPLICATION, 2017–2025 (USD MILLION) 153
TABLE 146 UK: APHERESIS MARKET, BY END USER, 2017–2025 (USD MILLION) 154
TABLE 147 SPAIN: KEY MACROINDICATORS FOR THE APHERESIS MARKET 155
TABLE 148 SPAIN: APHERESIS MARKET, BY PRODUCT, 2017–2025 (USD MILLION) 155
TABLE 149 SPAIN: APHERESIS DEVICES MARKET, BY TYPE, 2017–2025 (USD MILLION) 155
TABLE 150 SPAIN: APHERESIS MARKET, BY PROCEDURE, 2017–2025 (USD MILLION) 156
TABLE 151 SPAIN: THERAPEUTIC APHERESIS MARKET, BY PRODUCT 2017–2025 (USD MILLION) 156
TABLE 152 SPAIN: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2017–2025 (USD MILLION) 156
TABLE 153 SPAIN: APHERESIS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION) 157
TABLE 154 SPAIN: CENTRIFUGATION APHERESIS MARKET, BY TYPE 2017–2025 (USD MILLION) 157
TABLE 155 SPAIN: APHERESIS MARKET, BY APPLICATION, 2017–2025 (USD MILLION) 157
TABLE 156 SPAIN: APHERESIS MARKET, BY END USER, 2017–2025 (USD MILLION) 158
TABLE 157 ROE: APHERESIS MARKET, BY PRODUCT, 2017–2025 (USD MILLION) 158
TABLE 158 ROE: APHERESIS DEVICES MARKET, BY TYPE, 2017–2025 (USD MILLION) 159
TABLE 159 ROE: APHERESIS MARKET, BY PROCEDURE, 2017–2025 (USD MILLION) 159
TABLE 160 ROE: THERAPEUTIC APHERESIS MARKET, BY PRODUCT 2017–2025 (USD MILLION) 159
TABLE 161 ROE: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE 2017–2025 (USD MILLION) 160
TABLE 162 ROE: APHERESIS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION) 160
TABLE 163 ROE: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2017–2025 (USD MILLION) 160
TABLE 164 ROE: APHERESIS MARKET, BY APPLICATION, 2017–2025 (USD MILLION) 161
TABLE 165 ROE: APHERESIS MARKET, BY END USER, 2017–2025 (USD MILLION) 161
TABLE 166 ASIA PACIFIC: APHERESIS MARKET, BY COUNTRY, 2017–2025 (USD MILLION) 163
TABLE 167 ASIA PACIFIC: APHERESIS MARKET, BY PRODUCT, 2017–2025 (USD MILLION) 163
TABLE 168 ASIA PACIFIC: APHERESIS DEVICES MARKET, BY TYPE, 2017–2025 (USD MILLION) 163
TABLE 169 ASIA PACIFIC: APHERESIS MARKET, BY PROCEDURE, 2017–2025 (USD MILLION) 163
TABLE 170 ASIA PACIFIC: THERAPEUTIC APHERESIS MARKET, BY PRODUCT 2017–2025 (USD MILLION) 164
TABLE 171 ASIA PACIFIC: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2017–2025 (USD MILLION) 164
TABLE 172 ASIA PACIFIC: APHERESIS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION) 164
TABLE 173 ASIA PACIFIC: CENTRIFUGATION APHERESIS MARKET, BY TYPE 2017–2025 (USD MILLION) 165
TABLE 174 ASIA PACIFIC: APHERESIS MARKET, BY APPLICATION, 2017–2025 (USD MILLION) 165
TABLE 175 ASIA PACIFIC: APHERESIS MARKET, BY END USER, 2017–2025 (USD MILLION) 165
TABLE 176 CHINA: KEY MACROINDICATORS FOR THE APHERESIS MARKET 167
TABLE 177 CHINA: APHERESIS MARKET, BY PRODUCT, 2017–2025 (USD MILLION) 167
TABLE 178 CHINA: APHERESIS DEVICES MARKET, BY TYPE, 2017–2025 (USD MILLION) 167
TABLE 179 CHINA: APHERESIS MARKET, BY PROCEDURE, 2017–2025 (USD MILLION) 167
TABLE 180 CHINA: THERAPEUTIC APHERESIS MARKET, BY PRODUCT 2017–2025 (USD MILLION) 168
TABLE 181 CHINA: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2017–2025 (USD MILLION) 168
TABLE 182 CHINA: APHERESIS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION) 168
TABLE 183 CHINA: CENTRIFUGATION APHERESIS MARKET, BY TYPE 2017–2025 (USD MILLION) 169
TABLE 184 CHINA: APHERESIS MARKET, BY APPLICATION, 2017–2025 (USD MILLION) 169
TABLE 185 CHINA: APHERESIS MARKET, BY END USER, 2017–2025 (USD MILLION) 169
TABLE 186 BLOOD DONATIONS IN JAPAN, BY TYPE OF DONATION, 2015 170
TABLE 187 JAPAN: KEY MACROINDICATORS FOR THE APHERESIS MARKET 170
TABLE 188 JAPAN: APHERESIS MARKET, BY PRODUCT, 2017–2025 (USD MILLION) 171
TABLE 189 JAPAN: APHERESIS DEVICES MARKET, BY TYPE, 2017–2025 (USD MILLION) 171
TABLE 190 JAPAN: APHERESIS MARKET, BY PROCEDURE, 2017–2025 (USD MILLION) 171
TABLE 191 JAPAN: THERAPEUTIC APHERESIS MARKET, BY PRODUCT 2017–2025 (USD MILLION) 171
TABLE 192 JAPAN: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2017–2025 (USD MILLION) 172
TABLE 193 JAPAN: APHERESIS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION) 172
TABLE 194 JAPAN: CENTRIFUGATION APHERESIS MARKET, BY TYPE 2017–2025 (USD MILLION) 172
TABLE 195 JAPAN: APHERESIS MARKET, BY APPLICATION, 2017–2025 (USD MILLION) 173
TABLE 196 JAPAN: APHERESIS MARKET, BY END USER, 2017–2025 (USD MILLION) 173
TABLE 197 INDIA: KEY MACROINDICATORS FOR THE APHERESIS MARKET 174
TABLE 198 INDIA: APHERESIS MARKET, BY PRODUCT, 2017–2025 (USD MILLION) 174
TABLE 199 INDIA: APHERESIS DEVICES MARKET, BY TYPE, 2017–2025 (USD MILLION) 175
TABLE 200 INDIA: APHERESIS MARKET, BY PROCEDURE, 2017–2025 (USD MILLION) 175
TABLE 201 INDIA: THERAPEUTIC APHERESIS MARKET, BY PRODUCT 2017–2025 (USD MILLION) 175
TABLE 202 INDIA: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2017–2025 (USD MILLION) 176
TABLE 203 INDIA: APHERESIS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION) 176
TABLE 204 INDIA: CENTRIFUGATION APHERESIS MARKET, BY TYPE 2017–2025 (USD MILLION) 176
TABLE 205 INDIA: APHERESIS MARKET, BY APPLICATION, 2017–2025 (USD MILLION) 177
TABLE 206 INDIA: APHERESIS MARKET, BY END USER, 2017–2025 (USD MILLION) 177
TABLE 207 ROAPAC: APHERESIS MARKET, BY PRODUCT, 2017–2025 (USD MILLION) 178
TABLE 208 ROAPAC: APHERESIS DEVICES MARKET, BY TYPE, 2017–2025 (USD MILLION) 178
TABLE 209 ROAPAC: APHERESIS MARKET, BY PROCEDURE, 2017–2025 (USD MILLION) 178
TABLE 210 ROAPAC: THERAPEUTIC APHERESIS MARKET, BY PRODUCT 2017–2025 (USD MILLION) 178
TABLE 211 ROAPAC: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2017–2025 (USD MILLION) 179
TABLE 212 ROAPAC: APHERESIS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION) 179
TABLE 213 ROAPAC: CENTRIFUGATION APHERESIS MARKET, BY TYPE 2017–2025 (USD MILLION) 179
TABLE 214 ROAPAC: APHERESIS MARKET, BY APPLICATION, 2017–2025 (USD MILLION) 180
TABLE 215 ROAPAC: APHERESIS MARKET, BY END USER, 2017–2025 (USD MILLION) 180
TABLE 216 LATIN AMERICA: APHERESIS MARKET, BY COUNTRY, 2017–2025 (USD MILLION) 181
TABLE 217 LATIN AMERICA: APHERESIS MARKET, BY PRODUCT, 2017–2025 (USD MILLION) 181
TABLE 218 LATIN AMERICA: APHERESIS DEVICES MARKET, BY TYPE 2017–2025 (USD MILLION) 182
TABLE 219 LATIN AMERICA: APHERESIS MARKET, BY PROCEDURE 2017–2025 (USD MILLION) 182
TABLE 220 LATIN AMERICA: THERAPEUTIC APHERESIS MARKET, BY PRODUCT 2017–2025 (USD MILLION) 182
TABLE 221 LATIN AMERICA: THERAPEUTIC APHERESIS DISPOSABLES MARKET BY DISEASE TYPE, 2017–2025 (USD MILLION) 183
TABLE 222 LATIN AMERICA: APHERESIS MARKET, BY TECHNOLOGY 2017–2025 (USD MILLION) 183
TABLE 223 LATIN AMERICA: CENTRIFUGATION APHERESIS MARKET, BY TYPE 2017–2025 (USD MILLION) 183
TABLE 224 LATIN AMERICA: APHERESIS MARKET, BY APPLICATION 2017–2025 (USD MILLION) 184
TABLE 225 LATIN AMERICA: APHERESIS MARKET, BY END USER, 2017–2025 (USD MILLION) 184
TABLE 226 BRAZIL: KEY MACROINDICATORS FOR THE APHERESIS MARKET 185
TABLE 227 BRAZIL: APHERESIS MARKET, BY PRODUCT, 2017–2025 (USD MILLION) 185
TABLE 228 BRAZIL: APHERESIS DEVICES MARKET, BY TYPE, 2017–2025 (USD MILLION) 185
TABLE 229 BRAZIL: APHERESIS MARKET, BY PROCEDURE, 2017–2025 (USD MILLION) 186
TABLE 230 BRAZIL: THERAPEUTIC APHERESIS MARKET, BY PRODUCT 2017–2025 (USD MILLION) 186
TABLE 231 BRAZIL: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2017–2025 (USD MILLION) 186
TABLE 232 BRAZIL: APHERESIS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION) 187
TABLE 233 BRAZIL: CENTRIFUGATION APHERESIS MARKET, BY TYPE 2017–2025 (USD MILLION) 187
TABLE 234 BRAZIL: APHERESIS MARKET, BY APPLICATION, 2017–2025 (USD MILLION) 187
TABLE 235 BRAZIL: APHERESIS MARKET, BY END USER, 2017–2025 (USD MILLION) 188
TABLE 236 MEXICO: KEY MACROINDICATORS FOR THE APHERESIS MARKET 188
TABLE 237 MEXICO: APHERESIS MARKET, BY PRODUCT, 2017–2025 (USD MILLION) 189
TABLE 238 MEXICO: APHERESIS DEVICES MARKET, BY TYPE, 2017–2025 (USD MILLION) 189
TABLE 239 MEXICO: APHERESIS MARKET, BY PROCEDURE, 2017–2025 (USD MILLION) 189
TABLE 240 MEXICO: THERAPEUTIC APHERESIS MARKET, BY PRODUCT 2017–2025 (USD MILLION) 189
TABLE 241 MEXICO: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2017–2025 (USD MILLION) 190
TABLE 242 MEXICO: APHERESIS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION) 190
TABLE 243 MEXICO: CENTRIFUGATION APHERESIS MARKET, BY TYPE 2017–2025 (USD MILLION) 190
TABLE 244 MEXICO: APHERESIS MARKET, BY APPLICATION, 2017–2025 (USD MILLION) 191
TABLE 245 MEXICO: APHERESIS MARKET, BY END USER, 2017–2025 (USD MILLION) 191
TABLE 246 ROLA: APHERESIS MARKET, BY PRODUCT, 2017–2025 (USD MILLION) 191
TABLE 247 ROLA: APHERESIS DEVICES MARKET, BY TYPE, 2017–2025 (USD MILLION) 192
TABLE 248 ROLA: APHERESIS MARKET, BY PROCEDURE, 2017–2025 (USD MILLION) 192
TABLE 249 ROLA: THERAPEUTIC APHERESIS MARKET, BY PRODUCT 2017–2025 (USD MILLION) 192
TABLE 250 ROLA: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE, 2017–2025 (USD MILLION) 193
TABLE 251 ROLA: APHERESIS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION) 193
TABLE 252 ROLA: CENTRIFUGATION APHERESIS MARKET, BY TYPE 2017–2025 (USD MILLION) 193
TABLE 253 ROLA: APHERESIS MARKET, BY APPLICATION, 2017–2025 (USD MILLION) 194
TABLE 254 ROLA: APHERESIS MARKET, BY END USER, 2017–2025 (USD MILLION) 194
TABLE 255 MEA: APHERESIS MARKET, BY PRODUCT, 2017–2025 (USD MILLION) 195
TABLE 256 MEA: APHERESIS DEVICES MARKET, BY TYPE, 2017–2025 (USD MILLION) 195
TABLE 257 MEA: APHERESIS MARKET, BY PROCEDURE, 2017–2025 (USD MILLION) 196
TABLE 258 MEA: THERAPEUTIC APHERESIS MARKET, BY PRODUCT 2017–2025 (USD MILLION) 196
TABLE 259 MEA: THERAPEUTIC APHERESIS DISPOSABLES MARKET, BY DISEASE TYPE 2017–2025 (USD MILLION) 196
TABLE 260 MEA: APHERESIS MARKET, BY TECHNOLOGY, 2017–2025 (USD MILLION) 197
TABLE 261 MEA: CENTRIFUGATION APHERESIS MARKET, BY TYPE, 2017–2025 (USD MILLION) 197
TABLE 262 MEA: APHERESIS MARKET, BY APPLICATION, 2017–2025 (USD MILLION) 197
TABLE 263 MEA: APHERESIS MARKET, BY END USER, 2017–2025 (USD MILLION) 198
TABLE 264 PRODUCT LAUNCHES & APPROVALS (2017–2019) 205
TABLE 265 EXPANSIONS (2017–2019) 205
TABLE 266 PARTNERSHIPS, AGREEMENTS, AND COLLABORATIONS (2017–2019) 206
TABLE 267 ACQUISITIONS (2017) 207
TABLE 268 OTHER STRATEGIES (2018–2019) 207